Over the course of his career, he has managed global pharmacovigilance programs, clinical safety operations, and cross-functional teams supporting biologics, vaccines, medical devices, and advanced therapeutic medicinal products, including cell and gene therapies. His expertise spans clinical development, pharmacovigilance, medical monitoring, drug safety operations, safety strategy, medical review, signal management, regulatory-facing activities, safety system implementation, inspection readiness, and the coordination of global pharmacovigilance operations across products in development and post-marketing phases.

Before joining SentinelRX Life Sciences and Technologies, Dr. Thakkar held senior leadership roles at APCER Life Sciences, Cadila Pharma, Torrent Pharmaceuticals, Gujarat Cancer Research Institute, Cadila Healthcare, and Lambda Therapeutic Research. Across these roles, he contributed to Phase I–IV clinical trials, IND-related development activities, translational research, clinical strategy development, oncology and vaccine programs, novel drug delivery system (NDDS) product development, and regulatory submissions.

His leadership brings a strong medical, clinical, and drug safety perspective to *SentinelRX Life Sciences and Technologies’* operating model, strengthening its capabilities in clinical development, pharmacovigilance, medical monitoring, and drug safety operations. His experience supports scientifically rigorous, patient-centric, quality-driven, and strategically aligned clinical development and safety practices throughout the product lifecycle.

Anoop Singh is a clinical research and life sciences leader with more than 25 years of global experience supporting clinical development across sponsors, CROs, and research sites. Based in Bengaluru, he advises organisations across India, APAC, the Middle East, Australia, Europe, and the United States.

With more than 13 years in leadership roles across APAC and MEA, Anoop has worked across the clinical development lifecycle in more than 20 countries. His experience spans clinical operations, portfolio strategy, country and site selection, trial start-up and recruitment, sponsor–CRO governance, and the assessment and recovery of at-risk studies.

At SentinelRX Life Sciences, Anoop helps sponsors and healthcare organisations make informed, practical decisions about clinical development. He brings together operational experience and commercial perspective to help clients evaluate development plans, strengthen execution strategies, and identify and manage risks that can affect timelines, evidence generation, and asset value.

His work includes clinical development and go-to-market strategy, CRO and vendor oversight, asset and product acquisition assessments, and the commercialisation of university-led research, including programmes arising from research grants. He focuses on turning complex development challenges into clear priorities and actionable plans.

Anoop’s approach is grounded in the realities of trial execution: aligning strategy with operational capability, building effective partnerships, and keeping study decisions focused on generating reliable evidence. His goal is to help organisations reduce avoidable development risk and move promising research forward with greater clarity and confidence.

Dr Jyoti Sabharwal is Director – UK and Qualified Person for Pharmacovigilance (UK QPPV) at SentinelRX Life Sciences and Technologies. With 15 years of professional experience, she brings a strong combination of clinical expertise and pharmaceutical safety leadership, having worked as a Physician and Senior Drug Safety Lead. Her expertise spans drug safety, pharmacovigilance, and regulatory compliance, supporting the safe and effective use of medicines. At SentinelRX, she leads UK operations and pharmacovigilance oversight, helping ensure patient safety and adherence to applicable regulatory requirements.